Novel retinoblastoma mutation abrogating the interaction to E2F2/3, but not E2F1, led to selective suppression of

Hideaki Toki1, Maki Inoue, Osamu Minowa

  • 1Team for Advanced Development and Evaluation of Human Disease Models, Riken BioResource Center, Tsukuba, Ibaraki, Japan.

Cancer Science
|August 5, 2014
PubMed

Insights

Novel mouse models with retinoblastoma gene (Rb1) mutations reveal cell-type-specific tumor development. The Rb1(D326V/+) mutant suppresses thyroid tumors by inactivating E2F1, but causes pituitary tumors, highlighting Rb protein

Area of Science:

  • Genetics
  • Cancer Biology
  • Developmental Biology

Background:

  • Mutant mouse models are crucial for understanding gene function and disease mechanisms.
  • The retinoblastoma gene (Rb1) plays a key role in cell cycle regulation and tumor suppression.

Purpose of the Study:

  • To generate and characterize novel mouse models with point mutations in the Rb1 gene.
  • To investigate the role of specific Rb1 mutations in tumorigenesis and their interaction with E2F transcription factors.

Main Methods:

  • N-ethyl-N-nitrosourea mutagenesis to create Rb1 point mutations in mice.
  • Tumor spectrum and incidence analysis in mutant mice.
  • Immunohistochemistry and protein interaction assays to study Rb1 and E2F family members.

Main Results:

  • Splice site mutations in Rb1 led to tumor profiles similar to Rb1 knockout mice.
  • The Rb1(D326V/+) missense mutant suppressed thyroid tumors by selectively inactivating E2F1.
  • Rb1(D326V/+) mice developed pituitary tumors, with differential E2F inactivation in anterior and intermediate lobes.
  • The D326V mutation affected Rb protein interaction with E2F1 but not E2F2/3.

Conclusions:

  • Rb protein's role in tumorigenesis is cell-type-dependent, mediated by differential E2F inactivation.
  • The N-terminal domain of Rb protein influences E2F binding and tumor suppression.
  • These novel Rb1 mutant mouse models are valuable for studying human Rb family mutations.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

2.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K